Translocator protein 18 kDa (TSPO) is an evolutionarily conserved 5-transmembrane domain protein, and has been considered as an important therapeutic target for the treatment of pain. We have recently reported the in vitro and in vivo pharmacological characterization of koumine as a TSPO positive allosteric modulator (PAM), more precisely ago-PAM. However, the probe dependence in the allostery of koumine is an important question to resolve, and the possible analgesic mechanism of koumine remains to be clarified. Here, we report the in vivo evaluation of the allostery of koumine when orthosteric ligand PK11195 was used and preliminarily explore the possible analgesic mechanism of koumine associated with neurosteroids. We find that koumine is an ago-PAM of the PK11195-mediated analgesic effect at TSPO, and the analgesic mechanism of this TSPO ago-PAM may be associated with neurosteroids as the analgesic effects of koumine in the formalin-induced inflammatory pain model and chronic constriction injury-induced neuropathic pain model can be antagonized by neurosteroid synthesis inhibitor aminoglutethimide. Although our results cannot fully clarify the allosteric modulatory effect of koumine, it further prove the allostery in TSPO and provide a solid foundation for koumine to be used as a new clinical candidate drug to treat pain.

Keywords: koumine, allostery, translocator protein 18 kDa, probe dependence, neurosteroid

INTRODUCTION

Gelsemium elegans Benth. is indigenous to Southeast Asia, particularly China (Jin et al., 2014), and was first recorded in the earliest extant pharmaceutical monograph Divine Farmer’s Classic of Materia Medica (Shen Nong Ben Cao Jing) in China. In view of its obvious analgesic effect, the roots and leaves of G. elegans Benth. have been utilized orally or in dressings by the Hani ethnicity in the Naban River Watershed National Nature Reserve, Yunnan, China, for the treatment of bone fracture, stomachache and kidney pain (Ghorbani et al., 2011). Alkaloids are the main active ingredients of G. elegans Benth. Early clinical studies showed that the parenteral solution of crude alkaloid extraction has a significant analgesic effects on cancerous pain and colic caused by visceral smooth muscle...
spasm, with the analgesic efficiency reaching 90% (Chen, 1984). However, its further clinical use was restricted by its narrow therapeutic index. Koumine is the most abundant alkaloid in G. elegans Benth. with low toxicity (Jin et al., 2014), our previous series of studies showed that koumine has potent analgesic effect and no morphine-like tolerance or dependence. Therefore, it is of great value to develop koumine as a new candidate drug for pain treatment (Xu et al., 2012; Ling et al., 2014; Qiu et al., 2015; Xiong et al., 2017; Jin et al., 2018a; Jin et al., 2018b; Jin et al., 2021).

Translocator protein 18 kDa (TSPO) is an evolutionarily conserved 5-transmembrane domain protein previously known as peripheral benzodiazepine receptor (Papadopoulos et al., 2006). Genetic knockout studies have shown that although TSPO is not critical for the maintenance of baseline adrenal and gonadal steroidogenesis (except under stress or in aging), it can impair the total steroidogenic output (Banati et al., 2014; Morohaku et al., 2014; Tu et al., 2014; Fan et al., 2015; Owen et al., 2017; Barron et al., 2018). Given that TSPO ligands have important therapeutic effects in inflammatory and neuropathic pain (DalBo et al., 2004; Wei et al., 2013; Liu et al., 2016), TSPO is considered an important therapeutic target for the treatment of pain. In recent years, several studies have implied that there may be allosterism in TSPO (Narlawar et al., 2015; Jaipuria et al., 2017; Barron et al., 2018). Given that TSPO ligands have important therapeutic effects in inflammatory and neuropathic pain (Narlawar et al., 2015; Jaipuria et al., 2017; Barron et al., 2018), however, further investigations are still needed.

We have recently reported the in vitro and in vivo pharmacological characterization of koumine as a TSPO positive allosteric modulator (PAM), more precisely ago-PAM, and further demonstrated the allosterism in TSPO. Although the allosteric mechanisms of koumine was still unknown, our findings indicated that TSPO PAM may be a novel avenue for the treatment of inflammatory and neuropathic pain (Xiong et al., 2021). Notably, the allosteric interaction between an allosteric ligand and a protein is dependent on the orthosteric ligand (probe) used, that is probe dependence (Wootten et al., 2013). Our previous work focused on Ro5-4864 (one of the classical TSPO orthosteric ligands), the magnitude of the allosteric effect between koumine and TSPO when other TSPO orthosteric ligands were used remains to be examined. In addition, the results of our previous in vitro experiments showed that koumine did not show any allosteric modulatory effect in the synthesis of neurosteroid (Xiong et al., 2021). However, considering that koumine is a high-affinity ligand of TSPO and that the analgesic effect of TSPO ligands such as Ro5-4864 can be antagonized by neurosteroid synthesis inhibitor in vivo (Wei et al., 2013), whether koumine exerts analgesic effects in vivo through neurosteroidogenesis is also worthy of further study.

Given these findings, the aim of the current study was to evaluate the allosteric modulatory effect of koumine when the orthosteric ligand PK11195 was used and preliminarily explore the possible analgesic mechanism of koumine associated with neurosteroids. First, the effect of koumine on the analgesic effect of PK11195 in vivo was explored. Then, the possible analgesic mechanism of koumine was explored in the presence of a neurosteroidogenesis inhibitor in two pain models: the formalin-induced inflammatory pain model and the chronic constriction injury (CCI) model of neuropathic pain.

MATERIALS AND METHODS

Chemicals and Reagents
The dried rhizome of G. elegans Benth. was obtained from Bozhou Guotao Pharmaceutical Co., Ltd., Anhui (China). Koumine (purity >99%, UPLC) was isolated from G. elegans Benth. using pH-zone-refining countercurrent chromatography and the chemical identity of koumine was verified by MS and NMR, as described previously (Su et al., 2011). PK11195, Ro5-4864 and aminoglutethimide (AMG) were purchased from Sigma-Aldrich (United States).

Animals
Male ICR mice and male Sprague-Dawley rats (20 ± 2 g and 140 ± 10 g, respectively) were provided by the Beijing Vital River Laboratory Animal Technology Co., Ltd., China. A 12 h light/dark cycle with controlled temperatures of 20–26°C and 40–70% humidity was maintained in the barrier housing facility. Food and water were available ad libitum throughout the study period. All experimental procedures were performed according to the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals with approval from the Committee of Ethics of Fujian Medical University, China.

Formalin Test
The formalin test was carried out according to Dubuisson and Dennis (1977), with minor modifications. In brief, adult male ICR mice were individually placed in a transparent plastic box for adaptation, at least 30 min prior to injection of formalin. Each animal received a s.c. injection of 10 μl of 5% formalin solution into the plantar surface of the right hindpaw. The total licking time of the right hindpaw at 0–5 min (phase I) and 11–60 min (phase II) was recorded. PK11195 and koumine were injected s.c. 30 min or 40 min prior to formalin administration, respectively. To assess the interaction between koumine and PK11195, separate groups of mice were administrated koumine or vehicle and 10 min later PK11195 were given. For the antagonist study, i.p. AMG was administered 40 min before koumine, PK11195 or Ro5-4864 injection, and 70 min prior to formalin injection. PK11195, Ro5-4864 and AMG were dissolved in DMSO and diluted in sterile physiological saline (0.9% NaCl) to the appropriate concentration, and the final concentration of DMSO injected into animal was 5%. Koumine was dissolved in sterile physiological saline (0.9% NaCl) directly. The mock vehicle group was injected with 5% DMSO in saline.

Chronic Constriction Injury Model
The rat model of neuropathic pain by unilateral ligation of sciatic nerve was performed in rats as described earlier (Bennett and Xie, 1988). Briefly, SD rats were anesthetized by isoflurane delivered using an anesthetic machine. The right common sciatic nerve was dissected, exposed, and ligated at the level of the midhigh using 4 chromic gut (4-0) ties, separated by a 1 mm interval. After ligation, the wound was sutured and the rats were allowed to recover. With the sciatic nerve ligated rats, only those with marked unilateral allodynia to mechanical stimulation (hind limb withdrawal thresholds in the ipsilateral side/contralateral side <0.75) and with no major motor impairment were selected for further...
studies. The withdrawal thresholds of ipsilateral hind limbs were measured using the procedures described below. On the 9th day after surgery, i.p. AMG was administered 40 min before Ro5-4864 or koumine injection, and the mechanical withdrawal threshold (MWT) was determined 50 min after the last injection. Ro5-4864 and AMG were dissolved in DMSO and diluted in sterile physiological saline (0.9% NaCl), and the final concentration of DMSO was 5%. Koumine was dissolved in sterile physiological saline (0.9% NaCl) directly, and then diluted to the specified concentration. The mock vehicle group was injected with 5% DMSO in saline.

**Measurement of Mechanical Allodynia**

To assess mechanical allodynia, a 2390 Model electronic von Frey apparatus (IITC Life Science Inc., Woodland Hills, CA, United States) was used to determine ipsilateral hind limb withdrawal threshold evoked by stimulation of the hind paw as described by Mittrirattanakul et al. (2006) with minor modifications. Briefly, rat stood on a metal grid, the center of the hind paw was stimulated using the von Frey filament applied up to a maximum strength of 55 g or until the point of paw withdrawal. The threshold at which withdrawal occurred was automatically registered. The triplicate measurements were made at an interval of approximately 5 min, and the mean of these threshold values for each hind paw was used.

**Data and Statistical Analysis**

Data are presented as the mean ± SEM and were analyzed using SPSS software (version 19.0, SPSS Inc.). The comparison between the two groups was analyzed by independent samples t-test, and multiple comparisons were compared by one-way ANOVA followed by LSD post hoc test. Statistical significance for all of the analysis was determined at $p < 0.05$.

**RESULTS**

**Koumine Augments PK11195-Mediated Analgesic Effects in a Formalin-Induced Inflammatory Pain Model**

To evaluate the probe dependence of koumine, the formalin-induced inflammatory pain model was selected. According to the
preliminary experimental results of our research group, koumine produced a dose-dependent antinociceptive effect in phase II, 0.4 mg/kg koumine is ineffective on its own but can significantly augment the Ro5–4864-mediated analgesic effect, indicating that koumine is a PAM of Ro5–4864-mediated analgesic effect at TSPO, more precisely ago-PAM, that is, allosteric modulators exhibit PAM effects at low concentrations, and can also exert their effects alone at high concentrations, showing allosteric agonist effects (Schwartz and Holst, 2007; Garai et al., 2018; Liu et al., 2016), only Ro5–4864 was selected as the orthosteric agonist of koumine. Koumine is an ago-PAM of PK11195-mediated analgesic effect at TSPO, more precisely ago-PAM, that is, allosteric modulators that koumine could exert analgesic effect alone at high dose, showing allosteric agonist effects. Therefore, 10 mg/kg and 7 mg/kg koumine were selected in the formalin-induced inflammatory pain model and CCI model of neuropathic pain in this manuscript, respectively (Xiong et al., 2021). As shown in Figure 2, the one-way ANOVA revealed significant among-group differences in the biting time in phase II (F(7, 68) = 8.170, p < 0.001, Figure 2A). Post hoc LSD multiple comparison tests showed that 0.5 mg/kg PK11195 and Ro5–4864 produced a significant antinociceptive effect in phase II, and these analgesic effects were reversed by AMG, which was consistent with previous findings (DalBo et al., 2004). The TSPO ago-PAM koumine 10 mg/kg alone also exerted a prominent analgesic effect; similarly, the analgesic effect of koumine was dependent on neurosteroids because AMG prevented the effect (Figure 2A). The analgesic mechanism of koumine associated with neurosteroids was also studied in the CCI-induced neuropathic pain model. Since PK11195 has no analgesic effect in the neuropathic pain model (Liu et al., 2016), only Ro5–4864 was selected as the orthosteric ligand in this model. The results also showed that AMG abolished the analgesic effects of Ro5–4864 and koumine (Figure 2B), indicating that the analgesic mechanism of koumine may be associated with neurosteroids.

**DISCUSSION**

In the present study, we report the in vivo evaluation of the allostericity of koumine when orthosteric ligand PK11195 was used and preliminarily explore the possible allosteric mechanism of koumine. Koumine is an ago-PAM of PK11195-mediated analgesic effects at TSPO. Furthermore, the analgesic mechanism of the TSPO ago-PAM koumine may be associated with neurosteroids because AMG can abolish the analgesic effects of koumine in inflammatory and neuropathic pain models.

Allosteric modulator mainly include PAM, negative allosteric modulator and neutral allosteric ligand. Probe dependence is one of the main characteristics of allosterly. For a given receptor, the...
allosteric interaction of the allosteric modulator depends on the probe used, and for different probes, the allosteric modulator may have a different allosteric effect (Wootten et al., 2013). For example, TCN-201 is a negative allosteric modulator of glycine efficacy but a neutral allosteric ligand of glutamate activity at the N-methyl-D-aspartate receptor (Christopoulos et al., 2014). We recently studied the allosteric of koumine with TSPO in a formalin-induced inflammatory pain model, collagen-induced arthritis model and CCI model in which Ro5-4864 was used (Xiong et al., 2021). The results showed that when koumine (an ineffective dose) was combined with Ro5-4864, it significantly enhanced the analgesic and anti-inflammatory effects of Ro5-4864. PK11195 also has analgesic effects in the formalin-induced inflammatory pain model, and the allosteric of koumine when orthosteric ligand PK11195 is used remains to be clarified. In the current study, we found that koumine prominently augmented the PK11195-mediated analgesic effect in phase II but have no significant effect on phase I in a formalin-induced inflammatory pain model, manifesting that koumine is an ago-PAM of the PK11195-mediated analgesic effect at TSPO. In addition to PK11195 and Ro5-4864, TSPO also has other orthosteric ligands, such as cholesterol. The probe dependence of allosteric between koumine and TSPO when other TSPO orthosteric ligands are used remains to be further studied.

Noteworthily, only 0.0008 and 0.5 mg/kg of PK11195 have analgesic effect in phase I, and the effect is not dose-dependent. Both our research group and other research groups have observed that the effects of TSPO orthosteric ligand (such as PK11195) in phase I are not dose-dependent (DalBo et al., 2004; Xiong et al., 2021). One possible explanation for this observation is that the pain in phase I and phase II may be different. Phase I may be due to immediate and direct effects on sensory receptors, in contrast, phase II may be due to an inflammatory response (Hunskaar et al., 1985; Rujjanawate et al., 2003). And this may also be one of the reasons why koumine shows different effects on phase I and phase II. Moreover, we also observed that koumine only enhanced the analgesic effect of 0.0008–0.02 mg/kg PK11195 but not 0.00016, 0.1 and 0.5 mg/kg PK11195 in the phase II of formalin-induced inflammatory pain model. This may be related to the limited enhancement effect of allosteric modulation, that is, when the concentration of orthosteric ligand is too low or too high, the function of orthosteric ligand in the absence or presence of ago-PAM has no significant difference. Similar phenomena have been observed by other research group (Ignatowska-Jankowska et al., 2015).

TSPO can impair the total steroidogenic output and plays a crucial role in neurosteroidogenesis. In addition, in the neuropathic pain model induced by spinal nerve ligation, Ro5-4864 can effectively inhibit mechanical allodynia and thermal hyperalgesia and the analgesic effect can be antagonized by AMG (Wei et al., 2013), suggesting that the TSPO ligand may exert analgesic effects through neurosteroids. Koumine is a specific ligand of TSPO that has a similar affinity to the typical TSPO ligand (Xiong et al., 2021). Preliminary studies by our research group have shown that koumine can increase the level of neurosteroids in the rat spinal cord of CCI neuropathy (Xu et al., 2012). Thus, we conjecture that the analgesic effect of koumine may also be related to neurosteroidogenesis. In this study, we found that the analgesic effect of Ro5-4864 or PK11195 in a formalin-induced inflammatory pain model and a CCI neuropathic pain model can be antagonized by AMG, which can also abolished the analgesic effect of koumine in these inflammatory and neuropathic pain models, indicating that the analgesic mechanism of koumine may be associated with neurosteroids.

Together, we investigated the allosteric of koumine extracted from G. elegans Benth. in vivo when the orthosteric ligand PK11195 was used and found that the analgesic mechanism of the TSPO ago-PAM koumine may be associated with neurosteroids. At the same time, due to the limitations of pharmacological methods, our research cannot fully confirm the allosteric modulatory effect of koumine on TSPO, and structure determination as a definitive evidence of allosteric modulator has yet to be further carried out (Christopoulos et al., 2014; Xiong et al., 2021). Our data further prove the allosteric in TSPO and provide a solid foundation for koumine to be used as a new clinical candidate drug to treat pain.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by the Committee of Ethics of Fujian Medical University, China.

AUTHOR CONTRIBUTIONS

CY designed the research; BX, WY, YL, GJ, YX, JY, HH, and MW performed research; BX and CY wrote the paper. All authors have read and approved the final version of the manuscript.

FUNDING

This study was supported by the following: the National Natural Science Foundation of China (Grants 81973309 to CY.; 81872879 to JY), the Drug Innovation Major Project of China (Grant 2018ZX09711001-003-024 to CY), the Industry-University-Research Cooperation Project of Fujian Province (Grant 2017Y4007 to CY), Fujian provincial health technology project (Grant 2019-CX-34 to JY), and Startup Fund for scientific research, Fujian Medical University (Grant 2018QH2001 to BX).

ACKNOWLEDGMENTS

We thank Dongmei Shi (Fujian Medical University, China) for her assistance in the identification of dried rhizome of G. elegans Benth.
REFERENCES

Banati, R. B., Middleton, R. J., Chan, R., Harty, C. R., Kam, W. W., Quin, C., et al. (2014). Positron Emission Tomography and Functional Characterization of a Complete PBR/TSPO Knockout. Nat. Commun. 5, 5452. doi:10.1038/ncomms6452

Barron, A. M., Ji, B., Kito, S., Suhara, T., and Higuchi, M. (2018). Steroidogenic Abnormalities in Translocator Protein Knockout Mice and Significance in the Aging Male. Biochem. J. 475 (1), 75–85. doi:10.1042/bj20170645

Bennett, G. J., and Xie, Y. K. (1988). A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation like Those Seen in Man. Pain 33 (1), 87–107. doi:10.1016/0304-3959(88)90299-6

Chen, Z. (1984). Extraction of Gelsemium Alkaloids and the Preliminary Clinical Study of Medicinal Plants Utilised by Hani Ethnicity in Naban River Watershed Model of Diabetic Neuropathy. Biol. Pharm. Bull. 37 (5), 858–864. doi:10.1248/bpb.b13-00843

Liu, X., Liu, H., Xu, S., Yang, J., and Yu, H. C. (2014). Anti-inflammatory and Neuroprotective Effects of Koumine, a Benth Alkaloid, in a Rat Model of Diabetic Neuropathy. Biol. Pharm. Bull. 37 (5), 858–864. doi:10.1248/bpb.b13-00843

Xiong, B., Jin, G., Xu, S., Yang, J., Liu, M., Xu, X., and Yu, C. X. (2018). Koumine Decreases Astrocyte-Mediated Neuroinflammation and Enhances Autophagy, Contributing to Neuropathic Pain from Chronic Constriction Injury in Rats. Front. Pharmacol. 9, 989. doi:10.3389/fphar.2018.00989

Ling, Q., Liu, M., Wu, M. X., Xu, Y., Yang, J., and Huang, H. H., et al. (2014). Anti-allodynic and Neuroprotective Effects of Koumine, a Benth Alkaloid, in a Rat Model of Neuropathic Pain. J. Neural Sci. 345, 154–1551. doi:10.1016/j.neurosci.0324-12.2013.11024

Nalawar, R., Werry, E. L., Scarf, A. M., Hanani, R., Chua, S. W., King, V. A., et al. (2015). First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). J. Med. Chem. 58 (21), 8743–8749. doi:10.1021/acs.jmedchem.5b01288

Owen, D. R., Fan, J., Campioli, E., Venugopal, S., Miziazk, A., Daly, E., et al. (2017). TSPO Mutations in Rats and a Human Polymorphism Impair the Rate of Steroid Synthesis. Biochem. J. 474 (23), 3985–3999. doi:10.1042/bj20170648

Papadopoulos, V., Baraldi, M., Guiart, T. R., Knudsen, T. B., Lacapère, J. J., Lindemann, P., et al. (2006). Translocator Protein (18kDa): New Nomenclature for the Peripheral-type Benzodiazepine Receptor Based on its Structure and Molecular Function. Trends Pharmacol. Sci. 27 (8), 402–409. doi:10.1016/j.tips.2006.06.005

Qi, H. Q., Yu, X., Jin, G. L., Yang, J., Liu, M., Li, S. P., et al. (2015). Koumine Enhances Spinal Cord 3α-Hydroxysteroid Oxidoreductase Expression and Activity in a Rat Model of Neuropathic Pain. Mol. Pain 11 (1), 46. doi:10.1186/1744-8013-11-46

Rojas, C., Stathis, M., Coughlin, J. M., Popper, M., and Slusher, B. S. (2018). The Low Affinity Binding of Second Generation Radiotracers Targeting TSPO Is Associated with a Unique Allosteric Binding Site. J. Neuroimmune Pharmacol. 13 (1), 1–5. doi:10.1007/s11481-017-9765-2

Ruijjanawate, C., Kanjanapothi, D., and Panthong, A. (2003). Pharmacological Effect and Toxicity of Alkaloids from Gelsemium Elegans Benth. J. Ethnopharmacol. 89 (1), 91–95. doi:10.1016/s0378-8741(03)00267-8

Schwartz, T. W., and Holst, B. (2007). Allosteric Enhancers, Allosteric Agonists and Ago-Allosteric Modulators: where Do They Bind and How Do They Act? Trends Pharmacol. Sci. 28 (8), 366–373. doi:10.1016/j.tips.2007.06.008

Su, Y. P., Shen, J., Xu, Y., Zheng, M., and Yu, C. X. (2011). Preparative Separation of Alkaloids from Gelsemium Elegans Benth. Using pH-Zone-Refining Counter-current Chromatography. J. Chromatogr. A. 1218 (23), 3695–3698. doi:10.1016/j.chroma.2011.04.025

Tu, L. N., Morohaku, K., Mann, P. R., Pelton, S. H., Butler, W. R., Stocco, D. M., et al. (2014). Peripheral Benzodiazepine Receptor/translocator Protein Global Knock-Out Mice Are Viable with No Effects on Steroid Hormone Biosynthesis. J. Biol. Chem. 289 (40), 27444–27454. doi:10.1074/jbc.m114.578286

Wei, X. H., Wei, X., Chen, F. Y., Zang, Y., Xin, W. J., Pang, R. P., et al. (2013). The Universal Binding of Second Generation Radiotracers Targeting TSPO Is Associated with a Unique Allosteric Binding Site. J. Neuroimmune Pharmacol. 13 (1), 1–5. doi:10.1007/s11481-017-9765-2

Xiong, B., Jin, G., Xu, Y., Wu, Y., and Yang, J. (2017). Identification of Koumine as a Translocator Protein 18 kDa Positive Allosteric Modulator for the Treatment of Inflammatory and Neuropathic Pain. Front. Pharmacol. 12, 1692917. doi:10.3389/fphar.2021.692917

Xiong, B. J., Xu, Y., Jin, G. L., Liu, M., and Yang, J. (2017). Allosteric Effects and Pharmacologic Mechanisms of the Gelsemium Alkaloid Koumine on a Rat Model of Postoperative Pain. Sci. Rep. 7 (1), 14269. doi:10.1038/s41598-017-14714-0

Xiong, B., Jin, G., Xu, Y., You, W., Liu, H., Yang, J., et al. (2021). Identification of Koumine as a Translocator Protein 18 kDa Positive Allosteric Modulator for the Treatment of Inflammatory and Neuropathic Pain. Front. Pharmacol. 12, 692917. doi:10.3389/fphar.2021.692917
Allopregnanolone. *Pharmacol. Biochem. Behav.* 101 (3), 504–514. doi:10.1016/j.pbb.2012.02.009

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xiong, You, Luo, Jin, Wu, Xu, Yang, Huang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.